Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined With Osimertinib in Patients With Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

NCT04772235 is registered in ClinicalTrials.gov with Instituto Oncológico Dr Rosell as lead sponsor.

NCT NCT04772235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04772235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined With Osimertinib in Patients With Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
Lead sponsor
Instituto Oncológico Dr Rosell
Phase
Phase 1
Overall status
Unknown status
Start date
February 11, 2022
Completion date
June 30, 2026
Enrollment
32 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc